A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
about
A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinComparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesCross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsExtensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationHeterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.HIV/AIDS vaccines: a need for new concepts?Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection.A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Health service use and household expenditure during terminal illness due to AIDS in rural Tanzania.Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.Advances in HIV-1 Vaccine Development.Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.
P2860
Q28743092-0B223F84-931C-4D46-BCC9-D8D45EC32933Q33645053-8884FC06-0081-4D00-B5E0-D654281CD464Q33803217-21D2CB81-BDDA-4B13-82DC-44D0D79E5BD2Q33819493-E05F2F8E-1166-4AB8-9C39-D5F82F182104Q33960361-0476A3EA-595C-4D34-926C-9041A8F4FBFFQ35828002-3AC2A155-B3D7-4CDC-A5DC-E3443A6B5BDCQ36162593-5BE4234B-736C-4BE2-B474-1F25B0EB79C9Q37009569-8F3E8F7F-74E3-42B7-BB61-B426AF15D455Q37344236-2B411B2F-5F48-4764-86B9-34B2BC699FE2Q38749319-BE09CA0A-2007-40CA-9E49-5F6859A23D56Q39583691-9ED3725D-E267-4693-A6D0-0C6D9BDB8FE1Q39699309-86812293-E02A-493A-832A-5890841D0EA8Q43950004-46E28A3A-0144-4B37-9063-537E71578895Q45745783-8F16BD6F-4A92-4346-82FE-EB030187A4C8Q52609661-8C2E62FB-918C-4EBC-A603-8FE90777A25BQ52655238-552FF66E-521D-4FD3-AF62-1465C8334BAC
P2860
A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@en
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@nl
type
label
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@en
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@nl
prefLabel
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@en
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@nl
P2093
P1433
P1476
A clinically relevant HIV-1 su ...... unodeficiency virus infection.
@en
P2093
Deschamps M
Van Der Meide P
Von Hoegen P
P304
P356
10.1097/00002030-199805000-00002
P407
P577
1998-03-01T00:00:00Z